Vertex Pharmaceuticals Inc / Ma: Form 10-K for the period ended Dec 31, 2013
Filed with the SEC on Feb 11, 2014 and accepted by EDGAR at Feb 11, 2014, 21:38 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2013-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2013-10-01 to 2013-12-31 | $351.2m | us-gaap:Revenues |
| Revenue | 12 months2013-01-01 to 2013-12-31 | $1.21bn | us-gaap:Revenues |
| Cost of revenue | 3 months2013-10-01 to 2013-12-31 | $13.3m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 12 months2013-01-01 to 2013-12-31 | $89.0m | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2013-10-01 to 2013-12-31 | $249.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 12 months2013-01-01 to 2013-12-31 | $918.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2013-10-01 to 2013-12-31 | $75.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 12 months2013-01-01 to 2013-12-31 | $362.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2013-10-01 to 2013-12-31 | −$274.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2013-01-01 to 2013-12-31 | −$903.4m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2013-10-01 to 2013-12-31 | −$155.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 12 months2013-01-01 to 2013-12-31 | −$288.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2013-10-01 to 2013-12-31 | $44.3m | us-gaap:NetIncomeLoss |
| Net income | 12 months2013-01-01 to 2013-12-31 | −$445.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2013-10-01 to 2013-12-31 | $0.19 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2013-01-01 to 2013-12-31 | −$1.98 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2013-10-01 to 2013-12-31 | $0.19 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2013-01-01 to 2013-12-31 | −$1.98 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2013-10-01 to 2013-12-31 | 235,717,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 12 months2013-01-01 to 2013-12-31 | 224,906,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2013-01-01 to 2013-12-31 | −$51.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2013-01-01 to 2013-12-31 | $51.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2013-12-31 | $569.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2013-12-31 | $1.59bn | us-gaap:AssetsCurrent |
| Total assets | At period end2013-12-31 | $2.32bn | us-gaap:Assets |
| Current liabilities | At period end2013-12-31 | $397.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2013-12-31 | $962.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2013-12-31 | $1.36bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000875320-14-000015. Last ingested by Listed: Nov 11, 2026, 01:11 ET. Listed shows no prices and gives no investment advice.